Musculoskeletal
Integrity & Recovery
Building and repairing musculoskeletal tissue requires fine-tuned coordination of cellular growth signals. Transcriptomics lets us track myogenic and atrophy-associated transcripts over time.
Reading Muscle Genes
DXA measures lean mass and bone density directly. But the molecular cues driving muscle hypertrophy or muscle wasting (atrophy) shift in hours.
MYOD1, MYOG, TRIM63 and FBXO32 are skeletal-muscle transcripts. Measuring them requires a muscle sample; they are not recoverable at meaningful abundance from a blood draw. Where this panel runs on blood, treat these targets as research-stage rather than as a readout of your muscle.
Key Pathway Targets
Myoblast Determination Protein 1
Transcription factor induced early after satellite cell activation and marking commitment to differentiation.
Myogenic Factor 4
Coordinates late-stage skeletal muscle differentiation, essential for muscle fiber fusion and repair.
Insulin-Like Growth Factor 1
Drives localized muscle protein synthesis, satellite cell proliferation, and hypertrophy.
MuRF1 / Atrogin-1
The two best-characterised atrophy-associated E3 ubiquitin ligases. Their substrates differ, and both are induced transcriptionally under disuse (PMID 25096180).
Why DNA Tells Only Half the Musculoskeletal Story
Your DNA carries common variants in genes such as ACTN3 and MSTN. Effects of the ACTN3 R577X variant on performance are small and inconsistent, and common MSTN variants have no established effect on muscle phenotype in humans. None of this changes over your lifetime.
Transcriptomics (RNA) measures gene expression as it is happening, in the cells the sample contains. Because transcription responds to conditions rather than inheritance, a transcript panel reflects the state of these genes at the moment the sample was taken.
Protein Panels vs. Transcriptomics
DXA measures lean mass and bone density directly. Transcriptomics measures the gene transcription upstream of them. The two describe different layers of the same biology.
| Protein Marker | What It Measures | RNA Target |
|---|---|---|
| DXA Body Scan | Imaging-based measurement of lean mass and bone density. | IGF1 / MYOD1 |
| Serum Creatine Kinase | Measures severe mechanical muscle damage after it has occurred. | TRIM63 / FBXO32 |
| Systemic IGF-1 | Reflects general liver-derived IGF-1; does not capture local muscle synthesis. | MYOG |
WHAT A TRANSCRIPTIONAL PANEL DOES NOT TELL YOU
- × That you have, or do not have, any medical condition. This panel reports gene activity, not diagnoses.
- × Whether a therapy is working. Transcript levels move for many reasons — sleep, a recent infection, the time of day, how long since you last ate or trained — and a change in them is not evidence that any intervention succeeded or failed.
- × What your results will be next month. Every value describes the moment the sample was drawn. Single-timepoint transcript measurements carry substantial within-person variability.
- × What is happening in a tissue the sample did not come from. These panels run on a blood sample. A blood transcript level is not a muscle, liver, brain or adipose measurement.
Hypertrophy vs. Catabolism: The Molecular Balance
Skeletal muscle mass reflects the balance between protein synthesis and protein breakdown. The Akt/mTOR and FoxO pathways that set that balance are controlled by protein phosphorylation, so this panel does not measure them directly — it reads the myogenic and atrophy-associated transcripts that sit alongside them (PMID 28283069).
Satellite Activation
Mechanical loading activates quiescent satellite cells, and MYOD1 is induced downstream as an early marker of that activation rather than initiating it (PMID 26140708). The quiescence marker PAX7 is not on this panel.
Anabolic Synthesis
Local IGF1 expression increases, signaling through PI3K and Akt to raise translational efficiency and, more slowly, ribosome biogenesis.
Fiber Fusion
Myogenin (MYOG) drives the late differentiation programme. The membrane fusion that joins cells into a multinucleated myofiber is carried out by Myomaker and Myomerger, which are not on this panel (PMID 31648852).
Proteasomal Breakdown
Disuse induces both atrophy E3 ligases. MuRF1 ubiquitinates thick-filament proteins (PMID 19506036), while Atrogin-1's characterised targets are MyoD and the translation initiation subunit eIF3-f (PMID 18354498). The proteasome does the degrading.
Upregulating Lean Mass Integrity
These interventions apply targeted mechanical tension and nutritional cofactors to drive protein synthesis pathways and suppress muscle loss.
Progressive Resistance Exercise
Triggers mechanotransduction pathways, associated with higher IGF1 transcription over the hours and days following a training bout. This panel measures total IGF1 and does not resolve splice variants.
Essential Amino Acids
Dietary supplementSestrin2 binds GATOR2 and inhibits mTORC1. Leucine binds Sestrin2 and disrupts that interaction, relieving the inhibition (PMID 26449471). The downstream translation step is protein-level and not measured by this panel.
Creatine Monohydrate
Dietary supplementBuffers ATP resynthesis through the phosphocreatine system (PMID 10893433) and raises total body water — though direct measurement found no shift between the intracellular and extracellular compartments (PMID 12937471). One 12-week human trial reported higher myogenin and MRF-4 with training, and no effect on MyoD or Myf5 (PMID 12783039).
Therapies That Act on These Pathways
These therapies act on genes this panel reports. Biomeme does not prescribe, supply, recommend or evaluate any of them, and listing one here is not a claim that it works. Several are available only by prescription; some are not approved for any use. Where the published evidence is thin or points the other way, the card says so.
BPC-157
Not approved for any useStudied in preclinical models for effects on tissue repair signaling. Not approved for any use, and there are no published human trials. This panel carries no tendon, ligament or angiogenic target.
TB-500
Not approved for any useStudied in preclinical models for effects on cell migration. Not approved for any use, and there are no published human trials.
Testosterone / TRT
Prescription only · Controlled substance (Schedule III)Prescription testosterone is a Schedule III controlled substance, approved for specific medical conditions. Biomeme makes no claim about its use for any other purpose.
HGH
Prescription onlyPrescription growth hormone, approved only for specific medical conditions. Biomeme makes no claim about its use for any other purpose. This panel carries no collagen or connective-tissue target.
Scientific Citations
- [1] Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107-1213.
- [2] Willoughby DS, Rosene JM. Effects of oral creatine and resistance training on myogenic regulatory factor expression. Med Sci Sports Exerc. 2003;35(6):923-929.
- [3] Powers ME, Arnold BL, Weltman AL, et al. Creatine Supplementation Increases Total Body Water Without Altering Fluid Distribution. J Athl Train. 2003;38(1):44-50.
- [4] Lagirand-Cantaloube J, Offner N, Csibi A, et al. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J. 2008;27(8):1266-1276.
- [5] Cohen S, Brault JJ, Gygi SP, et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol. 2009;185(6):1083-1095.
- [6] Bodine SC, Baehr LM. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am J Physiol Endocrinol Metab. 2014;307(6):E469-484.
- [7] Dumont NA, Bentzinger CF, Sincennes MC, Rudnicki MA. Satellite Cells and Skeletal Muscle Regeneration. Compr Physiol. 2015;5(3):1027-1059.
- [8] Wolfson RL, Chantranupong L, Saxton RA, et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science. 2016;351(6268):43-48.
- [9] Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960-976.
- [10] Petrany MJ, Millay DP. Cell Fusion: Merging Membranes and Making Muscle. Trends Cell Biol. 2019;29(12):964-973.
The Biomeme Molecular Ecosystem
From deep whole-transcriptome sequencing in the laboratory to rapid point-of-care instrumentation in the field.
High-Depth RNA Sequencing
Processed at One Health Labs, Biomeme's CLIA-certified laboratory, using Illumina NovaSeq high-depth paired-end RNA sequencing. Samples are collected in venous PAXgene blood RNA tubes to stabilize cellular transcription at the moment of draw.
Biomeme/5 Handheld Platform
Beyond central-lab genomics, Biomeme engineers patented, battery-powered real-time PCR instruments. Our deployable hardware brings decentralized molecular detection directly to the field and clinical points of care.
Curious how we measure this?
Learn about the foundational science of Transcriptomics and how Biomeme brings molecular profiling to the point of need.
Ready to Learn More?
Explore how Biomeme's capabilities are being deployed across the Wellness landscape.
ABOUT THESE PANELS
Biomeme's wellness transcriptomic panels are general wellness products. They report gene activity to support a healthy lifestyle. They are not intended to diagnose, treat, cure, mitigate or prevent any disease or condition, and they are not a substitute for evaluation by a licensed healthcare professional. Results describe the state of the measured transcripts at the moment the sample was taken.